Clinical trial OASIS II
A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma (OASIS II)
| Cancers | |
|---|---|
| Organ | Lymphoma |
| Trial status | Trial closed for recruitment |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | Lysarc |
| EudraCT Identifier | 2020-004910-37 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04802590 |
| Last update |